DAY ONE BIOPHARMACEUTICALS I (DAWN)

US23954D1090 - Common Stock

13.5225  -1.67 (-10.98%)

Fundamental Rating

3

Overall DAWN gets a fundamental rating of 3 out of 10. We evaluated DAWN against 588 industry peers in the Biotechnology industry. While DAWN has a great health rating, there are worries on its profitability. DAWN is valued expensive and it does not seem to be growing.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DAWN has reported negative net income.
In the past year DAWN has reported a negative cash flow from operations.
DAWN had negative earnings in each of the past 5 years.
In the past 5 years DAWN always reported negative operating cash flow.

1.2 Ratios

DAWN has a Return On Assets (-50.24%) which is in line with its industry peers.
DAWN has a better Return On Equity (-54.51%) than 64.90% of its industry peers.
Industry RankSector Rank
ROA -50.24%
ROE -54.51%
ROIC N/A
ROA(3y)-49.95%
ROA(5y)-56.95%
ROE(3y)-52.68%
ROE(5y)-65.8%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DAWN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

8

2. Health

2.1 Basic Checks

DAWN has more shares outstanding than it did 1 year ago.
DAWN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 24.58 indicates that DAWN is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 24.58, DAWN belongs to the best of the industry, outperforming 94.52% of the companies in the same industry.
There is no outstanding debt for DAWN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 24.58
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 12.72 indicates that DAWN has no problem at all paying its short term obligations.
DAWN's Current ratio of 12.72 is amongst the best of the industry. DAWN outperforms 86.47% of its industry peers.
A Quick Ratio of 12.72 indicates that DAWN has no problem at all paying its short term obligations.
DAWN has a Quick ratio of 12.72. This is amongst the best in the industry. DAWN outperforms 86.47% of its industry peers.
Industry RankSector Rank
Current Ratio 12.72
Quick Ratio 12.72

More info and screens

1

3. Growth

3.1 Past

DAWN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.68%.
EPS 1Y (TTM)-9.68%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 25.69% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-12.19%
EPS Next 2Y6.77%
EPS Next 3Y20.48%
EPS Next 5Y25.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

DAWN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DAWN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as DAWN's earnings are expected to grow with 20.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.77%
EPS Next 3Y20.48%

More info and screens

0

5. Dividend

5.1 Amount

DAWN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DAY ONE BIOPHARMACEUTICALS I

NASDAQ:DAWN (4/25/2024, 9:29:08 AM)

13.5225

-1.67 (-10.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.18B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -50.24%
ROE -54.51%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 12.72
Quick Ratio 12.72
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-9.68%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-12.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y